Pharming Group has nominated Fabrice Chouraqui as the successor to CEO Sijmen de Vries. His appointment will be subject to approval at an Extraordinary General Meeting of Shareholders (EGM).
Upon his appointment, Chouraqui will join the Board of Directors, while De Vries will step down as CEO. To ensure a smooth transition, De Vries will remain as a strategic advisor until December 31, 2025.
Richard Peters, Chairman of the Board of Directors, highlighted the expertise Chouraqui brings to Pharming:
“Fabrice is a highly experienced leader in the international pharmaceutical and biotechnology sectors. He brings extensive global expertise across the entire biopharmaceutical value chain, which will support Pharming in its next phase of growth.”
Chouraqui has held senior leadership roles at Novartis and Bristol-Myers Squibb, bringing a wealth of industry knowledge to Pharming.
With this appointment, Pharming reinforces its commitment to continuity and international expansion in the biotech sector.
With construction in full swing, the new University Sports Centre (USC) is set to open its doors on December 1, 2025. The first visitors will be welcomed in February 2026,...
The Dutch Research Council (NWO) is investing €197 million in 11 large-scale research infrastructure projects that benefit both science and society. Leiden University and Leiden...
20 November 2025, The winner of the Venture Challenge Fall 2025 was announced at the Dutch Life Sciences Conference. We are proud to share that Myriagon has been selected as this...